InsidersTradesSigma
Total declarations
Companies
▲ Purchases (4 ops.)
▼ Sales (2 ops.)
Insider track record
Board DirectorDisclosed buys
4
Disclosed sells
2
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the detailed record of transactions filed by Rowland Charles A Jr, Director. Insider active across 5 companies, notably Blueprint Medicines Corp. In total, 13 reports have been logged. Breakdown: 4 buys · 2 sells. Total volume traded: €508k. History available since 2 June 2021. The latest transaction was disclosed on 2 January 2026 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Rowland Charles A Jr
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations13 total
53,475 sharesCommon StockSEC:0001104659-26-012196:0
3,150 shares0Common Stock, par value $0.00001 per shareSEC:0001193125-26-003110:0
16,000 shares@ US$4.4860.8% of flowCommon Stock, par value $0.00001 per shareSEC:0001193125-25-254300:0
12,294 sharesOrdinary SharesSEC:0000950170-24-007074:0
192,960 shares@ US$1.3145.9% of flowCommon StockSEC:0001415889-23-015864:0
Canonical exit: 29 Feb 2024 (T+90)
40,000 shares@ US$1.08100.0% of flowCommon Stock, par value $0.00001 per shareSEC:0001209191-23-030796:0
15,750 shares@ US$5.2616.3% of flowCommon StockSEC:0001415889-22-009796:0
Canonical exit: 18 Dec 2022 (T+90)
17,147 shares@ US$5.4118.4% of flowCommon StockSEC:0001415889-22-009776:0
Canonical exit: 14 Dec 2022 (T+90)
18,784 shares@ US$5.20419.4% of flowCommon StockSEC:0001415889-22-009671:0
Canonical exit: 12 Dec 2022 (T+90)
8,496 shares@ US$0.17548.0% of flowOrdinary SharesSEC:0001104659-22-085790:0
777 shares@ US$1.2035.1% of flowOrdinary SharesSEC:0001104659-21-100288:0
17,500 shares0Ordinary SharesSEC:0001104659-21-098427:0
2,250 shares0Common StockSEC:0001179110-21-006417:0
13 of 13 declarations
About Rowland Charles A Jr
Rowland Charles A Jr is Administrateur and is reported in 13 filings in total. In the 13 sampled recent filings, the attributed transactions run from 2021-06-04 to 2026-02-09, with EUR 505477 of buys and EUR 2234 of sells. He is listed as Director at Generation Bio Co., Viking Therapeutics, Inc., Nabriva Therapeutics plc, Orchard Therapeutics plc, and Blueprint Medicines Corp.
